Surgery of Colorectal Liver Metastases Involving the Inferior Vena Cava: A Systematic Review

Author:

Serradilla-Martín Mario1ORCID,Oliver-Guillén José Ramón2ORCID,Ruíz-Quijano Pablo3,Palomares-Cano Ana4,de la Plaza-Llamas Roberto5ORCID,Ramia José Manuel6

Affiliation:

1. Department of Surgery, Instituto de Investigación Sanitaria Aragón, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain

2. Department of Surgery, Hospital Santa Bárbara, 42005 Soria, Spain

3. Department of Surgery, Hospital HM Sanchinarro, 28050 Madrid, Spain

4. Department of Surgery, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain

5. Department of Surgery, Hospital Universitario de Guadalajara, 19002 Guadalajara, Spain

6. Department of Surgery, Hospital General Universitario Dr. Balmis, 03010 Alicante, Spain

Abstract

Combined hepatic and inferior vena cava (IVC) resection is the only potentially curative treatment for patients with colorectal liver metastases (CRLM) involving the IVC. Most of the existing data come from case reports or small case series. In this paper, a systematic review based on the PICO strategy was performed in accordance with the PRISMA statement. Papers from January 1980 to December 2022 were searched in Embase, PubMed, and the Cochrane Library databases. Articles considered for inclusion had to present data on simultaneous liver and IVC resection for CRLM and report surgical and/or oncological outcomes. From a total of 1175 articles retrieved, 29, including a total of 188 patients, met the inclusion criteria. The mean age was 58.3 ± 10.8 years. The most frequent techniques used were right hepatectomy ± caudate lobe for hepatic resections (37.8%), lateral clamping (44.8%) for vascular control, and primary closure (56.8%) for IVC repair. The thirty-day mortality reached 4.6%. Tumour relapse was reported in 65.8% of the cases. The median overall survival (OS) was 34 months (with a confidence interval of 30–40 months), and the 1-year, 3-year, and 5-year OS were 71.4%, 19.8%, and 7.1%, respectively. In the absence of prospective randomized studies, which are difficult to perform, IVC resection seems to be safe and feasible.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference53 articles.

1. International Organization for Cancer Chronotherapy A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma;Zidani;Int. Organ. Cancer Chronother. Cancer,1999

2. Leucovorin and Fluorouracil with or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer;Figer;J. Clin. Oncol.,2000

3. Surgical therapy of hepatic colorectal metastasis;Fong;CA Cancer J. Clin.,1999

4. Resection of Nonresectable Liver Metastases from Colorectal Cancer After Neoadjuvant Chemotherapy;Bismuth;Ann. Surg.,1996

5. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer;Giacchetti;J. Clin. Oncol.,2000

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3